Vir Biotechnology (VIR) News Today

Vir Biotechnology, Inc. (NASDAQ: VIR) shares have moved higher as investors respond to regulatory progress for the company’s prostate-cancer program, although analyst estimate reductions and a bearish Zacks rating remain risks.

• Positive Sentiment: The FDA granted Fast Track designation to VIR-5500, Vir’s PSMA-targeted Pro-XTEN® dual-masked T-cell engager being developed with Astellas Pharma for prostate cancer. Fast Track status may facilitate more frequent FDA interaction and potentially expedite the review process, strengthening the program’s development and commercial prospects. FDA Fast Track designation for VIR-5500
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $22 price target, implying substantial potential upside from recent trading levels. The firm raised its FY2030 EPS forecast modestly, to a loss of $0.29 per share from a loss of $0.34, suggesting improved longer-term expectations. HC Wainwright forecast for Vir Biotechnology
• Neutral Sentiment: Vir appointed David Liu as executive vice president and chief medical officer, effective October 12, 2026. The leadership addition could support clinical development, but the announcement does not immediately change the company’s financial outlook. David Liu appointed chief medical officer
• Neutral Sentiment: Investors are also watching upcoming SOLSTICE Phase 2 hepatitis D data, which could materially influence Vir’s investment narrative when released. No clinical results were reported in the article. SOLSTICE Phase 2 data outlook
• Negative Sentiment: HC Wainwright slightly lowered its FY2028 and FY2029 EPS forecasts, to losses of $1.71 and $1.26 per share, respectively, indicating continued expected losses and some pressure on near-term estimates.
• Negative Sentiment: Zacks Research downgraded Vir Biotechnology from “Hold” to “Strong Sell,” creating a notable counterweight to HC Wainwright’s bullish view. Zacks rating downgrade